Mr. Daniel P. O'Day is a Chairman & Chief Executive Officer at Gilead Sciences, Inc. He is on the Board of Directors at Galapagos NV, Flatiron Health, Inc., Pharmaceutical Manufacturers Association of America, Pharmaceutical Research & Manufacturers of America and Shanghai Roche Pharmaceuticals Ltd. Mr. O'Day was previously employed as a President & Chief Executive Officer by Roche Molecular Systems, Inc., a General Manager by Roche A/S Medicinalvarer OG Kemikalier, a Chief Operating Officer by Roche Diagnostics A/S, a Head-Business Unit, Arthritis & Respiratory by Roche Pharma Schweiz AG, a Chief Executive Officer by Roche Pharmaceuticals, Inc., a Head-Corporate Planning by Roche Diagnostics KK, and a CEO-Roche Pharmaceuticals by Roche Holding AG. He also served on the board at Foundation Medicine, Inc., Chugai Pharmaceutical Co., Ltd., Genentech, Inc. and Roche Diagnostics GmbH. He received his undergraduate degree from Georgetown University and an MBA from The Trustees of Columbia University in The City of New York.